Join the Clozaril group to help and get support from people like you.
Clozaril News
FDA Medwatch Alert: FDA Removes Risk Evaluation and Mitigation Strategy (REMS) Program for the Antipsychotic Drug Clozapine
August 27, 2025 – FDA Removes Risk Evaluation and Mitigation Strategies (REMS) Program for the Antipsychotic Drug Clozapine Neutropenia Risk Remains, but REMS No Longer Necessary and REMS May...
FDA Makes Access to Clozapine Easier for Patients With Schizophrenia
FRIDAY, Feb. 28, 2025 – The U.S. Food and Drug Administration has removed one hurdle faced by patients with schizophrenia when filling prescriptions for the antipsychotic medication clozapine. The...
FDA Medwatch Alert: Drug Safety Communication: Clozapine (Clozaril, Fazaclo ODT, Versacloz) - FDA Strengthens Warning That Untreated Constipation Can Lead to Serious Bowel Problems
ISSUE: FDA is strengthening an existing warning that constipation caused by the schizophrenia medicine clozapine (Clozaril, Fazaclo ODT, Versacloz, generics) can, uncommonly, progress to serious...
FDA Medwatch Alert: Clozapine: Drug Safety Communication - FDA Modifies Monitoring for Neutropenia; Approves New Shared REMS Program
ISSUE: FDA is making changes to the requirements for monitoring, prescribing, dispensing, and receiving the schizophrenia medicine clozapine, to address continuing safety concerns and current...
FDA Medwatch Alert: Clozaril (clozapine) - Jan 13, 2006
[Posted 01/13/2006] Novartis and FDA notified healthcare professionals of revisions to the BOXED WARNING, WARNINGS, CONTRAINDICATIONS, PRECAUTIONS (Information for Patients and...